
## Gilbert Koch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6886493/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Modeling of tumor growth and anticancer effects of combination therapy. Journal of Pharmacokinetics and Pharmacodynamics, 2009, 36, 179-197.	1.8	91
2	Release and Decay Kinetics of Copeptin vs AVP in Response to Osmotic Alterations in Healthy Volunteers. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 505-513.	3.6	65
3	Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. Clinical Pharmacokinetics, 2018, 57, 125-149.	3.5	49
4	Pharmacometrics and Machine Learning Partner to Advance Clinical Data Analysis. Clinical Pharmacology and Therapeutics, 2020, 107, 926-933.	4.7	46
5	A study on discrete and discrete fractional pharmacokinetics-pharmacodynamics models for tumor growth and anti-cancer effects. Computational and Mathematical Biophysics, 2019, 7, 10-24.	1.1	39
6	Enhanced early prediction of clinically relevant neonatal hyperbilirubinemia with machine learning. Pediatric Research, 2019, 86, 122-127.	2.3	37
7	Caffeine Citrate Dosing Adjustments to Assure Stable Caffeine Concentrations in Preterm Neonates. Journal of Pediatrics, 2017, 191, 50-56.e1.	1.8	31
8	Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations. Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41, 291-318.	1.8	30
9	Targetâ€Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 177-187.	2.5	30
10	Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells. Frontiers in Pharmacology, 2016, 7, 421.	3.5	27
11	Assessment of non-linear combination effect terms for drug–drug interactions. Journal of Pharmacokinetics and Pharmacodynamics, 2016, 43, 461-479.	1.8	27
12	Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells. Cancer Chemotherapy and Pharmacology, 2016, 77, 181-193.	2.3	24
13	Pharmacokinetics and Pharmacodynamics Models of Tumor Growth and Anticancer Effects in Discrete Time. Computational and Mathematical Biophysics, 2020, 8, 114-125.	1.1	13
14	Target-mediated drug disposition with drug–drug interaction, Part I: single drug case in alternative formulations. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 17-26.	1.8	12
15	Target mediated drug disposition with drug–drug interaction, Part II: competitive and uncompetitive cases. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 27-42.	1.8	12
16	Disease Progression Modeling to Evaluate the Effects of Enzyme Replacement Therapy on Kidney Function in Adult Patients with the Classic Phenotype of Fabry Disease. Kidney and Blood Pressure Research, 2017, 42, 1-15.	2.0	12
17	Multi-response model for rheumatoid arthritis based on delay differential equations in collagen-induced arthritic mice treated with an anti-GM-CSF antibody. Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39, 55-65.	1.8	10
18	Methadone dosing strategies in preterm neonates can be simplified. British Journal of Clinical Pharmacology, 2019, 85, 1348-1356.	2.4	10

**GILBERT KOCH** 

#	Article	IF	CITATIONS
19	Clinical Pharmacology and Pharmacometrics to Better Understand Physiological Changes During Pregnancy and Neonatal Life. Handbook of Experimental Pharmacology, 2019, 261, 325-337.	1.8	10
20	Mathematical Concepts in Pharmacokinetics and Pharmacodynamics with Application to Tumor Growth. Lecture Notes in Mathematics, 2013, , 225-250.	0.2	10
21	Caffeine preserves quiet sleep in preterm neonates. Pharmacology Research and Perspectives, 2020, 8, e00596.	2.4	9
22	Delayed logistic indirect response models: realization of oscillating behavior. Journal of Pharmacokinetics and Pharmacodynamics, 2018, 45, 49-58.	1.8	8
23	OptiDose: Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control. Journal of Optimization Theory and Applications, 2021, 189, 46-65.	1.5	8
24	General relationship between transit compartments and lifespan models. Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39, 343-355.	1.8	7
25	Characterization of Maternal and Neonatal Pharmacokinetic Behavior of Ceftazidime. Journal of Clinical Pharmacology, 2019, 59, 74-82.	2.0	7
26	The rhythm of a preterm neonate's life: ultradian oscillations of heart rate, body temperature and sleep cycles. Journal of Pharmacokinetics and Pharmacodynamics, 2021, 48, 401-410.	1.8	6
27	Distributed transit compartments for arbitrary lifespan distributions in aging populations. Journal of Theoretical Biology, 2015, 380, 550-558.	1.7	5
28	Delay differential equations based models in NONMEM. Journal of Pharmacokinetics and Pharmacodynamics, 2021, 48, 763-802.	1.8	4
29	Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition Model. Clinical Pharmacokinetics, 2022, 61, 143-154.	3.5	4
30	Facilitate Treatment Adjustment After Overdosing: Another Step Toward 21st-Century Medicine. Journal of Clinical Pharmacology, 2017, 57, 704-711.	2.0	3
31	Copeptin Kinetics and Its Relationship to Osmolality During Rehydration for Diabetic Ketoacidosis in Children. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4169-e4178.	3.6	3
32	Modeling of levothyroxine in newborns and infants with congenital hypothyroidism: challenges and opportunities of a rare disease multi-center study. Journal of Pharmacokinetics and Pharmacodynamics, 2021, 48, 711-723.	1.8	3
33	Not Only Preterm Neonates Mature but Also Traditional Dosing Regimens Have to Mature: The Role of Mathematical Modeling. Neonatology, 2021, 118, 114-115.	2.0	0
34	The Interaction between Sildenafil and Phenobarbital in Infants with Congenital Heart Defects. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO2-15-19.	0.0	0
35	MON-081 Mathematical Modeling of Residual Endogenous FT4 Synthesis and Exogenous L-Thyroxine Administration over the First 2 Years of Life in Infants with Congenital Hypothyroidism. Journal of the Endocrine Society, 2020, 4, .	0.2	0